FENC · ISSUER CIK 1211583
FENNEC PHARMACEUTICALS INC.
Between Aug 1, 2026 and Oct 29, 2026, 7 FENNEC PHARMACEUTICALS INC. insiders reported $0.00 of open-market purchases and $1.4M of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.4MInsider selling
−$1.4MNet open-market
Oct 13, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 202616:05 | Oct 12, 2026 | FENC | Chief Medical Officer | A · Grant | $5.53 | +3,846 | 13,533 | +40% | $21K | ||
| Oct 13, 202616:05 | Oct 12, 2026 | FENC | Chief Executive Officer, Director | A · Grant | $5.53 | +2,224 | 69,685 | +3% | $12K | ||
| Oct 13, 202616:05 | Oct 12, 2026 | FENC | Chief Commercial Officer | A · Grant | $5.53 | +2,326 | 24,013 | +11% | $13K | ||
| Oct 13, 202616:05 | Oct 12, 2026 | FENC | Chief Strategy Officer | A · Grant | $5.53 | +3,946 | 28,746 | +16% | $22K | ||
| Oct 13, 202616:05 | Oct 12, 2026 | FENC | CHIEF FINANCIAL OFFICER | A · Grant | $5.53 | +3,846 | 246,855 | +2% | $21K | ||
| Oct 1, 202616:05 | Sep 30, 2026 | FENC | Chief Medical Officer | A · Grant | — | +168 | 9,687 | +2% | — | ||
| Oct 1, 202616:05 | Sep 30, 2026 | FENC | Chief Commercial Officer | A · Grant | — | +168 | 21,687 | +1% | — | ||
| Oct 1, 202616:05 | Sep 30, 2026 | FENC | Chief Executive Officer, Director | A · Grant | — | +1,159 | 67,461 | +2% | — | ||
| Oct 1, 202616:05 | Sep 30, 2026 | FENC | Chief Strategy Officer | A · Grant | — | +156 | 24,800 | +1% | — | ||
| Oct 1, 202616:05 | Sep 30, 2026 | FENC | CHIEF FINANCIAL OFFICER | A · Grant | — | +1,703 | 243,009 | +1% | — | ||
| Sep 16, 202616:05 | Sep 15, 2026 | FENC | Director | S · Sell10b5-1 | $10.29 | −15,545 | 0 | -100% | −$160K | ||
| Sep 16, 202616:05 | Sep 15, 2026 | FENC | Director | M · Exercise10b5-1 | $2.11 | +15,545 | 15,545 | New | $33K | ||
| Sep 1, 202616:05 | Sep 1, 2026 | FENC | Former Director | S · Sell10b5-1 | $12.11 | −10,000 | 124,411 | -7% | −$121K | ||
| Sep 1, 202616:05 | Aug 31, 2026 | FENC | Former Director | A · Grant10b5-1 | — | +2,778 | 134,411 | +2% | — | ||
| Aug 31, 202620:15 | Aug 31, 2026 | FENC | Chief Medical Officer | S · Sell | $12.18 | −12,000 | 9,519 | -56% | −$146K | ||
| Aug 31, 202620:15 | Aug 31, 2026 | FENC | Chief Medical Officer | A · Grant | — | +168 | 21,519 | +1% | — | ||
| Aug 31, 202620:13 | Aug 31, 2026 | FENC | Chief Commercial Officer | A · Grant | — | +168 | 21,519 | +1% | — | ||
| Aug 31, 202620:12 | Aug 31, 2026 | FENC | Chief Strategy Officer | A · Grant | — | +156 | 24,644 | +1% | — | ||
| Aug 31, 202620:10 | Aug 31, 2026 | FENC | Chief Executive Officer, Director | A · Grant | — | +1,159 | 66,302 | +2% | — | ||
| Aug 31, 202620:09 | Aug 31, 2026 | FENC | CHIEF FINANCIAL OFFICER | A · Grant | — | +1,703 | 241,306 | +1% | — | ||
| Aug 28, 202617:42 | Aug 27, 2026 | FENC | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $11.78 | −75,000 | 217,675 | -26% | −$884K | ||
| Aug 28, 202617:42 | Aug 28, 2026 | FENC | CHIEF FINANCIAL OFFICER | M · Exercise10b5-1 | $5.10 | +21,928 | 239,603 | +10% | $112K | ||
| Aug 4, 202616:05 | Aug 3, 2026 | FENC | Former Director | S · Sell10b5-1 | $9.58 | −10,000 | 131,633 | -7% | −$96K | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | Chief Medical Officer | A · Grant | — | +168 | 21,351 | +1% | — | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | Chief Commercial Officer | A · Grant | — | +168 | 21,351 | +1% | — | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | Chief Strategy Officer | A · Grant | — | +156 | 24,488 | +1% | — | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | Chief Executive Officer, Director | A · Grant | — | +1,159 | 65,143 | +2% | — | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | Former Director | A · Grant | — | +2,778 | 141,633 | +2% | — | ||
| Aug 3, 202616:05 | Jul 31, 2026 | FENC | CHIEF FINANCIAL OFFICER | A · Grant | — | +1,703 | 292,675 | +1% | — |